Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4958

Sort by

Sort Order Select

Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Blood (2021) 137 (21): 2890–2901.

https://doi.org/10.1182/blood.2020008936

Published: 2021

Includes: Supplemental data

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

Blood (2020) 135 (18): 1531–1540.

https://doi.org/10.1182/blood.2019004369

Published: 2020

Includes: Supplemental data

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Paolo Strati, Ellen J. Schlette, Luisa M. Solis Soto, Daniela E. Duenas, Mariela Sivina, Ekaterina Kim, Michael J. Keating, William G. Wierda, Alessandra Ferrajoli, Hagop Kantarjian, Zeev Estrov, Nitin Jain, Philip A. Thompson, Ignacio I. Wistuba, Jan A. Burger

Blood (2020) 135 (7): 510–513.

https://doi.org/10.1182/blood.2019003570

Published: 2020

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII

Yanyan Shao, Wenman Wu, Guanqun Xu, Xuefeng Wang, Qiulan Ding

Blood (2019) 134 (20): 1745–1754.

https://doi.org/10.1182/blood.2018886069

Published: 2019

Includes: Supplemental data

Journal Articles

An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis

Veronica Asnaghi, MD, Maria Ballabio, MD, Philippe Jacqmin, Kathy de Graaf, Cristina De Min, MD

Blood (2019) 134 (Supplement_1): 2333.

https://doi.org/10.1182/blood-2019-123995

Published: 2019

Journal Articles

Thrombin Generation in Nephrotic Syndrome Is Dependent on Remission Status and Hypercholestrolemia

Bryce Kerlin, Amanda P. Waller, PhD, Jonathan P. Troost, PhD, Samir Parikh, MD, William E. Smoyer, MD, Matthias Kretzler, MD

Blood (2019) 134 (Supplement_1): 2422.

https://doi.org/10.1182/blood-2019-128680

Published: 2019

Journal Articles

Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

Hiroyuki Takamatsu, MD PhD, Takeshi Yoroidaka, MD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Mikio Ueda, MD PhD, Shinji Nakao, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 3083.

https://doi.org/10.1182/blood-2019-122398

Published: 2019

Journal Articles

Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma

Shiguang Ye, Lili Zhou, Shaoguang Li, Ping Li, Aibin Liang, MD PhD

Blood (2019) 134 (Supplement_1): 2818.

https://doi.org/10.1182/blood-2019-129666

Published: 2019

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Valentina Griggio, Candida Vitale, MD PhD, Chiara Salvetti, MD, Francesca Romana Mauro, MD, Daniela Pietrasanta, MD, Iolanda Donatella Vincelli, Lydia Scarfo, MD, Giovanni Del Poeta, MD, Gianluca Gaidano, MD PhD, Valter Gattei, MD, Robin Foà, MD, Mario Boccadoro, Marta Coscia, MD PhD

Blood (2019) 134 (Supplement_1): 3031.

https://doi.org/10.1182/blood-2019-125617

Published: 2019

Journal Articles

Clinical Features of Post-Transplant Lymphoproliferative Disease Are Different between Kidney-Transplant Recipients from a Cadaveric Donor and Those from a Living Donor

Shoko Oshima, MD, Akihito Shinohara, MD, Hideki Ishida, MD PhD, Miki Umeda, MD, Satoko Osanai, MD, Satoru Itoi, MD, Michiko Ryuzaki, MD, Yuki Izuka, MD, Aya Watanabe, MD, Norina Tanaka, MD PhD, Midori Ishiyama, MD PhD, Hiroshi Kazama, MD PhD, Kentaro Yoshinaga, MD PhD, Shotaro Hagiwara, MD PhD, Masayuki Shiseki, MD PhD, Junji Tanaka, MD PhD

Blood (2019) 134 (Supplement_1): 2910.

https://doi.org/10.1182/blood-2019-125601

Published: 2019

Journal Articles

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

James Yeung, MBBS, Ashlea Campbell, BSc MBBS FRACP FRCPA, Christian E Bryant, MBBS PhDFRACP FRCPA, Liane Khoo, MBBS PhDFRACP FRCPA, Scott Dunkley, MBBS FRACP FRCPA, Harry J Iland, MBBS FRACP FRCPA MHGSA, Stephen R Larsen, MBBS PhDFRACP FRCPA, Susan Moreton, MBBS FRACP FRCPA, Douglas E Joshua, BSc(Hons) MBBS DPhil FRACP FRCPA, Vinay Vanguru, MBBS FRACP FRCPA, Derek A McCulloch, BSc MBBChir PhDFRACP FRCPA, Danny Hsu, MBBS FRACP FRCPA, John Gibson, MBBS PhDFRACP FRCPA, P. Joy Ho, MBBS DPhil FRACP FRCPA, Christina Brown, MBBS PhDFRACP FRCPA

Blood (2019) 134 (Supplement_1): 2911.

https://doi.org/10.1182/blood-2019-131589

Published: 2019

Journal Articles

Long-Term Clinical and Molecular Remissions in Patients with Mantle Cell Lymphoma (MCL) Following High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Bernd Metzner, MD PhD, Jochen Casper, MD PhD, Koehne Claus-Henning, MD PhD, Andrea Renzelmann, MD, Thomas H. Mueller, MD PhD, Eduard K. Petershofen, MD PhD, Bernd Rosien, MD, Ruth Thole, MD, Andreas Voss, MD, Martin H. Dreyling, MD PhD, Eva Hoster, PhD, Wolfram Klapper, Christiane Pott, MD PhD

Blood (2019) 134 (Supplement_1): 2819.

https://doi.org/10.1182/blood-2019-122353

Published: 2019

Journal Articles

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

Jorge J. Castillo, MD, Joshua Gustine, MPH, Maria Demos, Andrew Keezer, BS, Kirsten Meid, MPH, Gloria G Chan, MS, Jiaji G Chen, Maria Luisa Guerrera, MD, Amanda Kofides, Manit Munshi, MS, Nicholas Tsakmaklis, Xia Liu, MD, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 2823.

https://doi.org/10.1182/blood-2019-125069

Published: 2019

Journal Articles

Krd Consolidation in Myeloma Patients with a Positive PET-CT after Standard First Line Treatment: A Phase II Study (CONPET)

Jakob Nordberg Nørgaard, MD, Niels Abildgaard, MD, Anna Lysén, MSc, Mona-Elisabeth R Revheim, MD PhD, James P Connelly, MD PhD, Fredrik H. Schjesvold, MD PhD

Blood (2019) 134 (Supplement_1): 3172.

https://doi.org/10.1182/blood-2019-125523

Published: 2019

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Ho Sup Lee, MD PhD, Chang-Ki Min, MD PhD, Kihyun Kim, MD, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, MD PhD, Dok Hyun Yoon, MD PhD, Cheolwon Suh, Ho-Jin Shin, MD PhD, Yeung-Chul Mun, MD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, Hye Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3114.

https://doi.org/10.1182/blood-2019-122404

Published: 2019

Journal Articles

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Timothy J Voorhees, MD, Natalie S Grover, MD, Anne Beaven, MD, Steven I Park, MD, J. Kaitlin Morrison, PhD, Catherine Joyce Arago Cheng, BS, Spencer Laing, BA, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Jonathan S Serody, MD

Blood (2019) 134 (Supplement_1): 3233.

https://doi.org/10.1182/blood-2019-122846

Published: 2019

NARROW

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis

AL patients don’t dare go without dara

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII

An Adaptive Design Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients with Non-Primary Hemophagocytic Lymphohistiocytosis

Thrombin Generation in Nephrotic Syndrome Is Dependent on Remission Status and Hypercholestrolemia

Comparison of Minimal Residual Disease Detection between the Manual and Automated Gating Strategies of Euroflow Next-Generation Flow in Patients with Multiple Myeloma

Good Tolerance and Durable Remission for Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Refractory/Relapsed Mantle Cell Lymphoma

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia

Clinical Features of Post-Transplant Lymphoproliferative Disease Are Different between Kidney-Transplant Recipients from a Cadaveric Donor and Those from a Living Donor

Safety and Efficacy of R-CEEP (Rituximab, Cyclophosphamide, Epirubicin, Etoposide, Prednisolone) in Elderly or Unfit Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Single-Centre Experience

Long-Term Clinical and Molecular Remissions in Patients with Mantle Cell Lymphoma (MCL) Following High-Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

Krd Consolidation in Myeloma Patients with a Positive PET-CT after Standard First Line Treatment: A Phase II Study (CONPET)

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only